22UA.XETRA BioNTech SE

Healthcare Biotechnology XETRA Stock Exchange
77.40 EUR
Close of Nov 6, 2026
68.30 105.70
Market cap
EUR 19.2B
P/E
-
P/B
1.11x
ROE
-8.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 22UA.XETRA undervalued?

Graham number

The Graham number of BioNTech SE cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BioNTech SE fundamental analysis

No fundamental analysis for BioNTech SE yet.

BioNTech SE stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast ca…

Full company profile